Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Oncology Letters
      • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Biomedical Reports
      • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • Information for Authors
    • Information for Reviewers
    • Information for Librarians
    • Information for Advertisers
    • Conferences
  • Language Editing
Spandidos Publications Logo
  • About
    • About Spandidos
    • Aims and Scopes
    • Abstracting and Indexing
    • Editorial Policies
    • Reprints and Permissions
    • Job Opportunities
    • Terms and Conditions
    • Contact
  • Journals
    • All Journals
    • Biomedical Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Experimental and Therapeutic Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Epigenetics
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Functional Nutrition
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Molecular Medicine
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • International Journal of Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Medicine International
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular and Clinical Oncology
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Molecular Medicine Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Letters
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • Oncology Reports
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
    • World Academy of Sciences Journal
      • Information for Authors
      • Editorial Policies
      • Editorial Board
      • Aims and Scope
      • Abstracting and Indexing
      • Bibliographic Information
      • Archive
  • Articles
  • Information
    • For Authors
    • For Reviewers
    • For Librarians
    • For Advertisers
    • Conferences
  • Language Editing
Login Register Submit
  • This site uses cookies
  • You can change your cookie settings at any time by following the instructions in our Cookie Policy. To find out more, you may read our Privacy Policy.

    I agree
Search articles by DOI, keyword, author or affiliation
Search
Advanced Search
presentation
Molecular Medicine Reports
Join Editorial Board Propose a Special Issue
Print ISSN: 1791-2997 Online ISSN: 1791-3004
Journal Cover
February-2019 Volume 19 Issue 2

Full Size Image

Sign up for eToc alerts
Recommend to Library

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

Medicine International

An International Open Access Journal Devoted to General Medicine.

Journal Cover
February-2019 Volume 19 Issue 2

Full Size Image

Sign up for eToc alerts
Recommend to Library

  • Article
  • Citations
    • Cite This Article
    • Download Citation
    • Create Citation Alert
    • Remove Citation Alert
    • Cited By
  • Similar Articles
    • Related Articles (in Spandidos Publications)
    • Similar Articles (Google Scholar)
    • Similar Articles (PubMed)
  • Download PDF
  • Download XML
  • View XML
Article Open Access

Theaflavins prevent cartilage degeneration via AKT/FOXO3 signaling in vitro

  • Authors:
    • Jun Li
    • Jianping Zheng
  • View Affiliations / Copyright

    Affiliations: Department of Orthopedics, Xiangyang Central Hospital, The Affiliated Hospital of Hubei College of Arts and Science, Xiangyang, Hubei 441021, P.R. China
    Copyright: © Li et al. This is an open access article distributed under the terms of Creative Commons Attribution License.
  • Pages: 821-830
    |
    Published online on: December 12, 2018
       https://doi.org/10.3892/mmr.2018.9745
  • Expand metrics +
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Cited By (CrossRef): 0 citations Loading Articles...

This article is mentioned in:



Abstract

Theaflavins (TFs) are the main bioactive polyphenols in tea and contribute to protection against oxidative stress. Excessive reactive oxygen species (ROS) accumulation can lead to the disruption of cartilage homeostasis. The present study examined the potential effects of TFs on H2O2‑induced cartilage degeneration in vitro. Cell Counting kit (CCK‑8) was used to determine cell viability, and flow cytometric analysis was used to detect ROS, apoptosis and DNA damage. Reverse transcription‑quantitative polymerase chain reaction (RT‑qPCR) and western blotting were used to detect the expression levels of target factors. The present study revealed that TFs effectively reduced the expression of catabolic factors, including matrix metalloproteinase‑13, interleukin‑1 and cartilage glycoprotein 39. TFs inhibited ROS generation in cartilage degeneration, and suppressed apoptosis and DNA damage caused by oxidative stress. TFs also downregulated the expression levels of cleaved caspase‑3 and B‑cell lymphoma 2‑associated X protein, and the DNA damage‑related genes, ATR serine/threonine kinase and ATM serine/threonine kinase. Furthermore, TFs enhanced the activity of glutathione peroxidase 1 and catalase, but reduced the expression levels of phosphorylated (p)‑AKT serine/threonine kinase (AKT) and p‑Forkhead box O3 (FOXO3)a. Conversely, the effects of TFs on apoptosis and DNA damage were reversed by persistent activation of AKT. In conclusion, TFs prevented cartilage degeneration via AKT/FOXO3 signaling in vitro. The present study suggested that TFs may be a potential candidate drug for the prevention of cartilage degeneration.

Introduction

Tea is one of the most widely consumed beverages worldwide, the health benefits of which have been recorded against numerous diseases in ancient China (1). In terms of worldwide distribution, black tea is mainly consumed in Western countries, whereas green tea is more common in Asian countries. It has been reported that tea polyphenols can inhibit osteoclast formation and differentiation in rats (2); however, the mechanism underlying the protective effects of tea polyphenols on cartilage cells have yet to be elucidated. Theaflavins (TFs) are the primary active polyphenols in black tea, which include theaflavin-3-gallate, theaflavin-3′-gallate and theaflavin-3-3′-digallate (3). TFs have been reported to possess numerous properties including antioxidant, antiviral and anticancer activities, in various biological processes (4,5). Cartilage degeneration is associated with the progression of osteoarthritis, and is mainly induced by oxidative stress (6). The present study aimed to explore the potential effect of TFs, in particular theaflavin-3-3′-digallate, on an in vitro model of cartilage degeneration and the related mechanisms.

Progressive cartilage destruction can be attributed to several factors (7). Among these factors, reactive oxygen species (ROS) are responsible for the maintenance of cartilage homeostasis; ROS act as the critical signaling intermediate of intracellular signaling pathways, including the phosphoinositide 3-kinase/protein kinase B and c-Jun N-terminal kinase pathways (8,9). Over-accumulation of ROS may lead to the disruption of cartilage homeostasis (10,11). In addition, apoptosis is considered to be associated with cartilage degeneration (12,13). It has been reported that overproduction of ROS can trigger intracellular DNA damage, which serves as a cellular stress factor (8). Furthermore, it has been demonstrated that Forkhead box (FOX) transcription factors are implicated in cell cycle progression, immune regulation, tumor growth and the aging process (14). FOXO proteins are able to regulate oxidative stress resistance through controlling downstream antioxidant targets, including glutathione peroxidase 1 (Gpx1) and catalase (CAT) (15,16). In addition, AKT serine/threonine kinase (AKT) serves important roles in cell survival and its activation can phosphorylate several downstream proteins, including FOXO3a. The transcriptional inactivation of FOXO3a can be induced by phosphorylation via AKT (17). Based on these findings, it is likely that AKT/FOXO signaling may be associated with the protective effect of TFs in cartilage cells.

The present study aimed to investigate the protective effect of TFs on cartilage cells and attempted to explore the underlying mechanisms.

Materials and methods

Cell culture and grouping

Human chondrocytes (cat. no. 4650; ScienCell Research Laboratories, Inc., San Diego, CA, USA) were cultured in a 6-well plate (1×105/well) at 37°C in a 5% CO2 incubator with Dulbecco's modified Eagle medium containing 10% fetal bovine serum (both Gibco; Thermo Fisher Scientific, Inc., Waltham, MA, USA) and 1% penicillin and streptomycin (Sangon Biotech Co., Ltd., Shanghai, China). Cells were fixed with 95% ethanol for 15 sec at room temperature and then stained with 1% toluidine blue (Beijing Solarbio Science & Technology Co., Ltd., Beijing, China) for 5 min at room temperature and observed under a light microscope (magnification, ×100). Theaflavin-3-3′-digallate (purity >90%) was purchased from Sigma-Aldrich (Merck KGaA, Darmstadt, Germany). At ~80% confluence, the cells were serum-starved overnight and were then divided into three treatment groups for comparison: i) Control group; ii) model group, in which cells were treated with 0.3 mM H2O2 for 6 h; and iii) TF pretreatment groups, in which cells were pretreated with various doses of TFs (10 and 20 µg/ml) for 12 h, followed by 6 h H2O2 incubation. The TF concentrations employed were based on previous literature (18,19). For the activation of AKT, cells were pretreated with 50 ng/ml insulin-like growth factor I (IGF-I; R&D Systems, Inc., Minneapolis, MN, USA) for 10 min prior to H2O2 or TF treatment, according to previous studies (20,21).

Cell Counting kit (CCK)-8 assay

The cells were serum starved overnight in a 96-well plate (1×105 cells/well), and were then treated with H2O2 (0.1–0.5 µM) in serum-free medium for various durations (6, 12, 24 and 48 h). A CKK-8 kit was used to detect cell viability, according to the manufacturer's protocol (Beijing Kangwei Century Biotechnology Co., Ltd., Beijing, China). Briefly, the CCK-8 solution was added to each well and the cells were incubated for 4 h at 37°C, after which, absorbance was measured at 450 nm using a microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA, USA).

ELISA assay

The cells were seeded at a density of 1×104 cells/well in a 96-well plate and were treated as aforementioned. Matrix metalloproteinase (MMP)-13 (cat. no. DY511) and interleukin (IL)-1β (cat. no. DLB50) activities were detected using ELISA kits (R&D Systems, Inc.), according to the manufacturer's protocols. The ELISA kit used to measure the expression of cartilage glycoprotein 39 (Cgp-39; cat. no. HC021) was purchased from Shanghai GeFan Biotechnology, Co., Ltd. (Shanghai, China).

Flow cytometric analysis of ROS levels

The cells (1×104 cells/well) were treated as aforementioned. Subsequently, the cells were stained with H2DCHF-DA (Invitrogen; Thermo Fisher Scientific, Inc.) for ROS measurement, as previously described (22). BD FACSCanto II (BD Biosciences, Franklin Lakes, NJ, USA) running BD CellQuest™ software version 3.3 (BD Biosciences) was used to perform flow cytometric analysis. All data are representatives of at least three independent experiments.

Flow cytometric analysis of apoptosis

The cells (1×105/well) were cultured in 6-well plates. An Annexin V/propidium iodide (PI) apoptosis kit (Invitrogen; Thermo Fisher Scientific, Inc.) was used to detect apoptosis. According to the manufacturer's protocol, Annexin-V and PI staining was analyzed using analyzed using a flow cytometer (BD FACSCanto II) with FACSDiva software version 6.1 (both BD Biosciences).

Flow cytometric analysis of DNA damage

According to a previous study (23), DNA damage was estimated using flow cytometry-based detection of γ-H2A histone family, member X (γ-H2AX). Briefly, the collected cells were suspended in BD Cytofix/Cytoperm fixation and permeabilization solution (BD Biosciences). After a 15-min incubation at 37°C, the cells were washed using PBS and blocked with 10% normal goat serum (Gibco; Thermo Fisher Scientific, Inc.) at 37°C for 1 h. Cells were incubated with anti-γ-H2AX (pS139) antibody (cat. no. ab26350; 1:100; Abcam, Cambridge, UK) at 4°C overnight and then incubated with fluorescein isothiocyanate-conjugated secondary antibodies (cat. no. ab7064; 1:1,000; Abcam) for 45 min at 37°C. Subsequently, the fluorescent signals were measured using a BD flow cytometer (BD Biosciences).

Total RNA isolation and reverse transcription-quantitative polymerase chain reaction (RT-qPCR)

Total RNA was isolated using RNAiso reagent (Takara Bio, Inc., Otsu, Japan). Subsequently, cDNA was reverse transcribed from total RNA using ReverTra Ace (Toyobo Life Science, Osaka, Japan) and oligo-dT (Takara Bio, Inc.), according to manufacturer's protocol. The mRNA expression levels were quantified using an ABI 7500 Real-time PCR system (Applied Biosystems; Thermo Fisher Scientific, Inc.) using AceQ qPCR SYBR Green Master Mix (Vazyme, Piscataway, NJ, USA). The thermocycling conditions were as follows: 95°C for 5 min, followed by 30 cycles of 94°C for 15 sec and 60°C for 30 sec, and final extension at 72°C for 5 min. Relative expression levels were calculated using the 2−ΔΔCq method (24). Primer sequences for RT-qPCR were as follows: ATR serine/threonine kinase (ATR) forward, 5′-GGAATCACGACTCGCTGA; AC-3′ reverse, 5′-AAATCGGCCCACTAGTAGCA-3′; ATM serine/threonine kinase (ATM) forward, 5′-CGAGGCGTACAATGGTGAAG-3′ and reverse, 5′-CCTCCGGCTAAGCGAAATTC-3′; B-cell lymphoma 2-associated X protein (Bax) forward, 5′-GAGCGGCGGTGATGGA-3′ and reverse, 5′-TGGATGAAACCCTGAAGCAAA-3′; and β-actin forward, 5′-CTCTTCCAGCCTTCCTTCC-3′; and reverse, 5′-AGCACTGTGTTGGCGTACAG-3′.

Western blot analysis

A Total Extraction Sample kit (Sigma-Aldrich; Merck KGaA) was used to extract total proteins. Protein concentration was determined using the Pierce™ BCA Protein Assay kit (Thermo Fisher Scientific, Inc.). The proteins (20 µg/lane) were separated by 10% SDS-PAGE and were then transferred onto a polyvinylidene fluoride membrane. To block non-specific proteins, non-fat milk (3%) was used to incubate the membrane for 2 h at room temperature. Following incubation with primary antibodies overnight at 4°C, the membrane was incubated with secondary antibodies for 2 h at room temperature, and the bands were developed using an enhanced chemiluminescence reagent (GE Healthcare Life Sciences, Little Chalfont, UK). Blot density was determined using Quantity One software version 4.6.9 (Bio-Rad Laboratories, Inc.). The primary antibodies used were as follows: Anti-ATR (cat. no. ab2905; 1:1,000), anti-Bax (cat. no. ab53154; 1:1,000; both Abcam, Cambridge, UK), anti-cleaved caspase-3 (cat. no. 9664; 1:1,000; Cell Signaling Technology, Inc., Danvers, MA, USA), anti-ATM (cat. no. ab78; 1:2,000), anti-γH2AX (cat. no. ab11175; 1:8,000; both Abcam), anti-phosphorylated (p)-AKT (cat. no. 13038; 1:1,000; Cell Signaling Technology, Inc.), anti-AKT1/2 (cat. no. ab182729; 1:5,000), anti-p-FOXO3a (cat. no. ab53287; 1:1,000; both Abcam), anti-FOXO3a (cat. no. 2497; 1:1,000; CST), anti-Gpx1 (cat. no. ab22604; 1:1,000), anti-CAT (cat. no. ab16731; 1:2,000; both Abcam) and anti-β-actin (cat. no. 4970; 1:1,000; Cell Signaling Technology, Inc.). Horseradish peroxidase-conjugated secondary antibodies (goat anti-rabbit; cat. no. ab205718; 1:2,000 and goat anti-mouse; cat. no. ab205719; 1:5,000) were obtained from Abcam.

Statistical analysis

All experiments were independently performed ≥3 times. Data are presented as the means ± standard deviation. GraphPad software version 6.0 (GraphPad Software, Inc., La Jolla, CA, USA) was used to compare differences between groups by one-way analysis of variance followed by Tukey's multiple comparisons test. P<0.05 was considered to indicate a statistically significant difference.

Results

TFs inhibit ROS generation in cartilage degeneration

The cartilage cells presented with spindle morphology, and toluidine blue staining was conducted to identify the cells. It was identified that the cytoplasm was stained light blue and the nucleus was stained dark blue, indicating that these cells were chondrocytes (Fig. 1A and B). Subsequently, CCK-8 assay was conducted to evaluate the effects of H2O2 on the viability of cartilage cells. It was demonstrated that cell viability was suppressed by H2O2 in a dose-dependent manner. A significant difference emerged in the group that was treated with 0.3 mM H2O2 for 6 h, in which cell viability was deceased by 14% (Fig. 1B). Therefore, 0.3 mM H2O2 was subsequently used to treat cartilage cells for 6 h, in order to mimic the progression of cartilage degeneration. To measure cartilage degeneration following H2O2 treatment, the expression levels of catabolic factors, MMP-13, IL-1β and Cgp-39, were detected. It was demonstrated that the expression levels of MMP-13, IL-1β and Cgp-39 were increased by H2O2, but were decreased by TF pretreatment (Fig. 2A). These findings suggested that TFs may inhibit cartilage degeneration. Furthermore, according to flow cytometric analysis, it was demonstrated that ROS levels were markedly decreased in the TF pretreatment groups (Fig. 2B and C).

Figure 1.

(A) Unstained and (B) toluidine blue-stained cartilage cells were observed under light microscope; magnification, ×100. (C) Effects of H2O2 on cartilage cells. Cells were treated with various doses of H2O2 (0.1, 0.2, 0.3, 0.4 and 0.5 mM) for 6, 12, 24 and 48 h. *P<0.05 and **P<0.01 vs. control.

Figure 2.

(A) Detection of catabolic factors, MMP-13, IL-1β and Cgp-39. (B) ROS production rate was determined following treatment with TFs and H2O2. (C) ROS levels were measured by flow cytometry. **P<0.01 vs. control; #P<0.05 and ##P<0.01 vs. MG; ^P<0.05, ^^P<0.01 vs. T1 + H2O2. Cgp, cartilage glycoprotein; IL, interleukin; MG, model group; MMP, matrix metalloproteinase; ROS, reactive oxygen species; T1, pretreatment with 10 µg/ml TFs; T2, pretreatment with 20 µg/ml TFs; TFs, theaflavins.

TFs suppress apoptosis and DNA damage following oxidative stress

The results of flow cytometric analysis revealed that H2O2-induced apoptosis was suppressed by pretreatment with TFs (Fig. 3A and B). DNA double-strand breaks (DSBs) are a type of detrimental DNA damage, for which γH2AX is considered a surrogate marker. In response to DSBs, H2AX is phosphorylated at Ser139 (γH2AX) (25). The present results demonstrated that TFs could decrease γH2AX expression compared with in the model group (Fig. 4A and B). In addition, western blotting confirmed that TFs inhibited the expression levels of γH2AX (Fig. 4C). The expression levels of apoptosis-associated factors, including cleaved caspase-3 and Bax, were decreased in the TF pretreatment groups compared with in the model group. The expression levels of DNA damage-response genes, ATM and ATR, were also decreased following TF pretreatment (Fig. 5A-C). However, the protein expression levels of ATR were slightly, but not significantly, increased in the T1 + H2O2 group.

Figure 3.

(A) Flow cytometric analysis of cartilage cell apoptosis. (B) Determination of cell apoptosis rate. **P<0.01 vs. control; #P<0.05 vs. MG; ^P<0.05 vs. T1 + H2O2. FITC, fluorescein isothiocyanate; MG, model group; PI, propidium iodide; T1, pretreatment with 10 µg/ml TFs; T2, pre-treatment with 20 µg/ml TFs; TFs, theaflavins.

Figure 4.

(A) Flow cytometric analysis of DNA damage in cartilage cells. (B) Determination of DNA damage rate. (C) Western blot analysis of the expression of γH2AX. **P<0.01 vs. control; ##P<0.01 vs. MG; ^^P<0.01 vs. T1 + H2O2. H2AX, H2A histone family, member X; MG, model group; T1, pretreatment with 10 µg/ml TFs; T2, pretreatment with 20 µg/ml TFs; TFs, theaflavins.

Figure 5.

(A) Quantitative analysis of Bax, ATR and ATM mRNA expression. (B and C) Western blot analysis of cleaved caspase-3, Bax, ATR and ATM. *P<0.05 and **P<0.01 vs. control; #P<0.05 and ##P<0.01 vs. MG; ^^P<0.01 vs. T1 + H2O2. ATM, ATM serine/threonine kinase; ATR, ATR serine/threonine kinase; Bax, B-cell lymphoma 2-associated X protein; MG, model group; T1, pretreatment with 10 µg/ml TFs; T2, pre-treatment with 20 µg/ml TFs; TFs, theaflavins.

TFs decrease the activity of AKT, FOXO3a, Gpx1 and CAT

Emerging evidences have demonstrated that FOXO proteins are important mediators of oxidative stress (15,16). Compared with in the model group, the protein expression levels of p-AKT and p-FOXO3a were mitigated by TF pretreatment, whereas the expression levels of Gpx1 and CAT were enhanced (Fig. 6A and B).

Figure 6.

(A and B) Western blot analysis of AKT, p-AKT, FOXO3a, p-FOXO3a, Gpx1 and CAT. **P<0.01 vs. control; #P<0.05 and ##P<0.01 vs. MG; ^^P<0.01 vs. T1 + H2O2. CAT, catalase; FOXO3a, Forkhead box O3a; MG, model group; Gpx, glutathione peroxidase 1; p-, phosphorylated; T1, pretreatment with 10 µg/ml TFs; T2, pre-treatment with 20 µg/ml TFs; TFs, theaflavins.

AKT activity is necessary for the protective effects of TFs

To further confirm the role of AKT in the present study, apoptosis and DNA damage were detected following treatment with the AKT activator, IGF-I. The results demonstrated that TF pretreatment did not significantly reverse H2O2-induced apoptosis following persistent activation of AKT (Fig. 7A and B). In addition, TF-induced inhibition of DNA damage was reversed following persistent activation of AKT (Fig. 8A-C).

Figure 7.

(A and B) Flow cytometric analysis of apoptosis. **P<0.01 vs. control; ^^P<0.01 vs. IGF-I + T2 + H2O2. FITC, fluorescein isothiocyanate; IGF, insulin-like growth factor; MG, model group; PI, propidium iodide; T1, pretreatment with 10 µg/ml TFs; T2, pre-treatment with 20 µg/ml TFs; TFs, theaflavins.

Figure 8.

(A and B) Flow cytometric analysis of DNA damage. (C) Western blot analysis was conducted to detect the expression of γH2AX. **P<0.01 vs. control; ##P<0.01 vs. MG; ^P<0.05 and ^^P<0.01 vs. IGF-I + T2 + H2O2. H2AX, H2A histone family, member X; IGF, insulin-like growth factor; MG, model group; T1, pretreatment with 10 µg/ml TFs; T2, pre-treatment with 20 µg/ml TFs; TFs, theaflavins.

Discussion

Tea is one of the most widely consumed beverages worldwide (26). The potential health benefits of tea have been widely reported, particularly with regards to the prevention of cardiovascular disorders and cancer. Phenols and polyphenols are the primary bioactive substances in tea that exert health effects (27); therefore, attention has been paid to the antioxidative effects of tea polyphenols (28). Cartilage degeneration is a serious complication of osteoarthritis, which is mainly caused by oxidative stress (29). A previous study demonstrated the positive function of tea polyphenols in maintaining bone homeostasis (2). TFs are the primary active content of tea phenols (30); however, little is currently known about the effects of TFs on cartilage degeneration.

Studies have revealed the connection between structural degeneration and biochemical markers (31–34). Several biochemical markers, including MMP-13 (32), IL-1β (33) and Cgp-39 (34), are used to diagnose patients with a high risk of joint degeneration. The present study demonstrated that TFs inhibited H2O2-mediated cartilage degeneration by decreasing the levels of MMP-13, IL-1β and Cgp-39. This study also aimed to illustrate the molecular mechanisms underlying the effects of TFs on the cartilage cells. The results demonstrated that ROS production was markedly increased in the model group, whereas pretreatment with TFs significantly decreased ROS levels. Furthermore, pretreatment with TFs reduced cell apoptosis and DNA damage caused by H2O2, and decreased the expression levels of cleaved caspase-3 and Bax, which are closely associated with cell apoptosis (35,36). The expression levels of ATR and ATM, which is the master kinase that controls the DNA damage check point (37,38), were decreased in the TF pretreatment groups compared with in the model group. These findings indicated that TFs may prevent cartilage matrix degeneration by inhibiting DNA damage and apoptosis. The inhibitory effects of TFs on apoptosis were supported by a recent study in PC12 neural cells (39). In addition, DNA damage can be modified by TFs in human lymphocytes (40). However, numerous studies have demonstrated that TFs inhibit proliferation and induce apoptosis in cancer cells (41–43). These contradictory results may be due to the distinct cell types used in each study model.

To explore the possible underlying mechanisms, the effects of TFs on the activity of AKT/FOXO3 signaling were investigated. It was noted that TFs mitigated the expression of p-AKT and p-FOXO3a, and enhanced Gpx1 and CAT activities compared with in the model group. It has previously been demonstrated that the reduced activity of AKT/FOXOs mitigates cell dysfunction in diabetic kidney disease (44). Notably, the present study revealed that TF-induced inhibition of apoptosis and DNA damage was reversed following persistent activation of AKT. Therefore, it may be hypothesized that the effects of TFs on cartilage cells may be tightly linked to AKT/FOXO signaling. Since phosphorylation of FOXO3 results in its inactivation, TFs may reduce inactivation of FOXO3 by suppressing AKT. However, this speculation was not validated in the present study. The protective effect of FOXO3 inactivation on cartilage still requires further investigation. In addition, the activity of FOXOs can be regulated by other signals (45); however, the regulation is rather complex, and parts of it are contradictory. For example, FOXO3 can be activated by the phosphorylation of 5′AMP-activated protein kinase, c-Jun N-terminal kinase and macrophage-stimulating 1 (46). Therefore, it would be useful to investigate how the upstream signals co-regulate FOXO3 signaling in future studies.

In conclusion, the present study demonstrated that TFs inhibited the ROS burst in cartilage destruction. TFs suppressed apoptosis and DNA damage by reducing the expression levels of cleaved caspase-3, Bax, ATR and ATM. Furthermore, TFs enhanced the activity of Gpx1 and CAT, and decreased the expression levels of p-AKT and p-FOXO3a. Notably, AKT signaling was necessary for the effects of TFs on apoptosis and DNA damage. The results of the present study demonstrated that TFs may be a potential candidate drug for the prevention of cartilage degeneration.

Acknowledgements

Not applicable.

Funding

No funding was received.

Availability of data and materials

All data generated or analyzed during this study are included in this published article.

Authors' contributions

JL and JZ designed the study, performed the experiments and performed the data analysis. JL wrote the manuscript. JL and JZ revised the manuscript.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1 

Graham HN: Tea: The plant and its manufacture; chemistry and consumption of the beverage. Prog Clin Biol Res. 158:29–74. 1984.PubMed/NCBI

2 

Oka Y, Iwai S, Amano H, Irie Y, Yatomi K, Ryu K, Yamada S, Inagaki K and Oguchi K: Tea polyphenols inhibit rat osteoclast formation and differentiation. J Pharm Sci. 118:55–64. 2012. View Article : Google Scholar

3 

Liu S, Lu H, Zhao Q, He Y, Niu J, Debnath AK, Wu S and Jiang S: Theaflavin derivatives in black tea and catechin derivatives in green tea inhibit HIV-1 entry by targeting gp41. Biochim Biophys Acta. 1723:270–281. 2005. View Article : Google Scholar : PubMed/NCBI

4 

Maron DJ, Lu GP, Cai NS, Wu ZG, Li YH, Chen H, Zhu JQ, Jin XJ, Wouters BC and Zhao J: Cholesterol-lowering effect of a theaflavin-enriched green tea extract: A randomized controlled trial. Arch Intern Med. 163:1448–1453. 2003. View Article : Google Scholar : PubMed/NCBI

5 

Lin JK, Chen PC, Ho CT and Lin-Shiau SY: Inhibition of xanthine oxidase and suppression of intracellular reactive oxygen species in HL-60 cells by theaflavin-3,3′-digallate, (−)-epigallocatechin-3-gallate, and propyl gallate. J Agric Food Chem. 48:2736–2743. 2000. View Article : Google Scholar : PubMed/NCBI

6 

Pap T and Korb-Pap A: Cartilage damage in osteoarthritis and rheumatoid arthritis-two unequal siblings. Nat Rev Rheumatol. 11:606–615. 2015. View Article : Google Scholar : PubMed/NCBI

7 

Hosseinzadeh A, Kamrava SK, Joghataei MT, Darabi R, Shakeri-Zadeh A, Shahriari M, Reiter RJ, Ghaznavi H and Mehrzadi S: Apoptosis signaling pathways in osteoarthritis and possible protective role of melatonin. J Pineal Res. 61:411–425. 2016. View Article : Google Scholar : PubMed/NCBI

8 

Lepetsos P and Papavassiliou AG: ROS/oxidative stress signaling in osteoarthritis. Biochim Biophys Acta. 1862:576–591. 2016. View Article : Google Scholar : PubMed/NCBI

9 

Yu SM and Kim SJ: Withaferin A-caused production of intracellular reactive oxygen species modulates apoptosis via PI3K/Akt and JNKinase in rabbit articular chondrocytes. J Korean Med Sci. 29:1042–1053. 2014. View Article : Google Scholar : PubMed/NCBI

10 

Chen AF, Davies CM, De Lin M and Fermor B: Oxidative DNA damage in osteoarthritic porcine articular cartilage. J Cell Physiol. 217:828–833. 2008. View Article : Google Scholar : PubMed/NCBI

11 

Davies CM, Guilak F, Weinberg JB and Fermor B: Reactive nitrogen and oxygen species in interleukin-1-mediated DNA damage associated with osteoarthritis. Osteoarthritis Cartilage. 16:624–630. 2008. View Article : Google Scholar : PubMed/NCBI

12 

Hashimoto S, Ochs RL, Komiya S and Lotz M: Linkage of chondrocyte apoptosis and cartilage degradation in human osteoarthritis. Arthritis Rheum. 41:1632–1638. 1998. View Article : Google Scholar : PubMed/NCBI

13 

Kim HA and Blanco FJ: Cell death and apoptosis in osteoarthritic cartilage. Curr Drug Targets. 8:333–345. 2007. View Article : Google Scholar : PubMed/NCBI

14 

Calnan DR and Brunet A: The FoxO code. Oncogene. 27:2276–2288. 2008. View Article : Google Scholar : PubMed/NCBI

15 

van der Horst A and Burgering BMT: Stressing the role of FoxO proteins in lifespan and disease. Nat Rev Mol Cell Biol. 8:440–450. 2007. View Article : Google Scholar : PubMed/NCBI

16 

Brigelius-Flohé R and Maiorino M: Glutathione peroxidases. Biochim Biophys Acta. 1830:3289–3303. 2013. View Article : Google Scholar : PubMed/NCBI

17 

García Z, Kumar A, Marqués M, Cortés I and Carrera AC: Phosphoinositide 3-kinase controls early and late events in mammalian cell division. EMBO J. 25:655–661. 2006. View Article : Google Scholar : PubMed/NCBI

18 

Wang W, Sun Y, Liu J, Wang J, Li Y, Li H and Zhang W: Protective effect of theaflavins on homocysteine-induced injury in HUVEC cells in vitro. J Cardiovasc Pharmacol. 59:434–440. 2012. View Article : Google Scholar : PubMed/NCBI

19 

Lahiry L, Saha B, Chakraborty J, Bhattacharyya S, Chattopadhyay S, Banerjee S, Choudhuri T, Mandal D, Bhattacharyya A, Sa G and Das T: Contribution of p53-mediated Bax transactivation in theaflavin-induced mammary epithelial carcinoma cell apoptosis. Apoptosis. 13:771–781. 2008. View Article : Google Scholar : PubMed/NCBI

20 

Wu CJ, O'Rourke DM, Feng GS, Johnson GR, Wang Q and Greene MI: The tyrosine phosphatase SHP-2 is required for mediating phosphatidylinositol 3-kinase/Akt activation by growth factors. Oncogene. 20:6018–6025. 2001. View Article : Google Scholar : PubMed/NCBI

21 

Yamada T, Takeuchi S, Fujita N, Nakamura A, Wang W, Li Q, Oda M, Mitsudomi T, Yatabe Y, Sekido Y, et al: Akt kinase-interacting protein1, a novel therapeutic target for lung cancer with EGFR-activating and gatekeeper mutations. Oncogene. 32:4427–4435. 2013. View Article : Google Scholar : PubMed/NCBI

22 

Fani S, Kamalidehghan B, Lo KM, Nigjeh SE, Keong YS, Dehghan F, Soori R, Abdulla MA, Chow KM, Ali HM, et al: Anticancer activity of a monobenzyltin complex C1 against MDA-MB-231 cells through induction of Apoptosis and inhibition of breast cancer stem cells. Sci Rep. 6:389922016. View Article : Google Scholar : PubMed/NCBI

23 

Li J, Guo YY, Wu W, Bai JL, Xuan ZQ, Yang J and Wang J: Detecting DNA damage of human lymphocytes exposed to 1,2-DCE with γH2AX identified antibody using flow cytometer assay. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi. 29:16–19. 2011.(In Chinese). PubMed/NCBI

24 

Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI

25 

Yu YK, Lu Y, Yu Y and Yang J: γH2AX: A biomarker for DNA double-stranded breaks. Chin J Pharm Tox. 19:237–240. 2005.

26 

Wang D, Gao Q, Wang T, Qian F and Wang Y: Theanine: the unique amino acid in the tea plant as an oral hepatoprotective agent. Asia Pac J Clin Nutr. 26:384–391. 2017.PubMed/NCBI

27 

Schneider C and Segre T: Green tea: Potential health benefits. Am Fam Physician. 79:591–594. 2009.PubMed/NCBI

28 

Tipoe GL, Leung TM, Hung MW and Fung ML: Green tea polyphenols as an anti-oxidant and anti-inflammatory agent for cardiovascular protection. Cardiovasc Hematol Disord Drug Targets. 7:135–144. 2007. View Article : Google Scholar : PubMed/NCBI

29 

Li YS, Xiao WF and Luo W: Cellular aging towards osteoarthritis. Mech Ageing Dev. 162:80–84. 2017. View Article : Google Scholar : PubMed/NCBI

30 

Morinobu A, Biao W, Tanaka S, Horiuchi M, Jun L, Tsuji G, Sakai Y, Kurosaka M and Kumagai S: (−)-Epigallocatechin-3-gallate suppresses osteoclast differentiation and ameliorates experimental arthritis in mice. Arthritis Rheum. 58:2012–2018. 2008. View Article : Google Scholar : PubMed/NCBI

31 

Bruyere O, Collette JH, Ethgen O, Rovati LC, Giacovelli G, Henrotin YE, Seidel L and Reginster JY: Biochemical markers of bone and cartilage remodeling in prediction of longterm progression of knee osteoarthritis. J Rheumatol. 30:1043–1050. 2003.PubMed/NCBI

32 

Attur M, Yang Q, Kirsch T and Abramson SB: Role of periostin and discoidin domain receptor-1 (DDR1) in the regulation of cartilage degeneration and expression of MMP-13. Osteoarthritis Cartilage. 24:S1562016. View Article : Google Scholar

33 

Goldring SR: Pathogenesis of bone and cartilage destruction in rheumatoid arthritis. Rheumatology (Oxford). 42 Suppl 2:ii11–ii16. 2003. View Article : Google Scholar : PubMed/NCBI

34 

Zivanović S, Rackov LP, Vojvodić D and Vucetić D: Human cartilage glycoprotein 39-biomarker of joint damage in knee osteoarthritis. Int Orthop. 33:1165–1170. 2009. View Article : Google Scholar : PubMed/NCBI

35 

Oltvai ZN, Milliman CL and Korsmeyer SJ: Bcl-2 heterodimerizes in vivo with a conserved homolog, Bax, that accelerates programmed cell death. Cell. 74:609–619. 1993. View Article : Google Scholar : PubMed/NCBI

36 

Porter AG and Jänicke RU: Emerging roles of caspase-3 in apoptosis. Cell Death Differ. 6:99–104. 1999. View Article : Google Scholar : PubMed/NCBI

37 

Lee JH and Paull TT: Activation and regulation of ATM kinase activity in response to DNA double-strand breaks. Oncogene. 26:7741–7748. 2007. View Article : Google Scholar : PubMed/NCBI

38 

Sancar A, Lindsey-Boltz LA, Unsal-Kaçmaz K and Linn S: Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints. Annu Rev Biochem. 73:39–85. 2004. View Article : Google Scholar : PubMed/NCBI

39 

Zhang J, Cai S, Li J, Xiong L, Tian L, Liu J, Huang J and Liu Z: Neuroprotective effects of theaflavins against oxidative stress-induced apoptosis in PC12 cells. Neurochem Res. 41:3364–3372. 2016. View Article : Google Scholar : PubMed/NCBI

40 

Alotaibi A, Bhatnagar P, Najafzadeh M, Gupta KC and Anderson D: Tea phenols in bulk and nanoparticle form modify DNA damage in human lymphocytes from colon cancer patients and healthy individuals treated in vitro with platinum-based chemotherapeutic drugs. Nanomedicine (Lond). 8:389–401. 2013. View Article : Google Scholar : PubMed/NCBI

41 

Adhikary A, Mohanty S, Lahiry L, Hossain DM, Chakraborty S and Das T: Theaflavins retard human breast cancer cell migration by inhibiting NF-kappaB via p53-ROS cross-talk. FEBS Lett. 584:7–14. 2010. View Article : Google Scholar : PubMed/NCBI

42 

Bhattacharya U, Halder B, Mukhopadhyay S and Giri AK: Role of oxidation-triggered activation of JNK and p38 MAPK in black tea polyphenols induced apoptotic death of A375 cells. Cancer Sci. 100:1971–1978. 2009. View Article : Google Scholar : PubMed/NCBI

43 

Schuck AG, Ausubel MB, Zuckerbraun HL and Babich H: Theaflavin-3,3′-digallate, a component of black tea: An inducer of oxidative stress and apoptosis. Toxicol In Vitro. 22:598–609. 2008. View Article : Google Scholar : PubMed/NCBI

44 

Kato M, Yuan H, Xu ZG, Lanting L, Li SL, Wang M, Hu MC, Reddy MA and Natarajan R: Role of the Akt/FoxO3a pathway in TGF-beta1-mediated mesangial cell dysfunction: A novel mechanism related to diabetic kidney disease. J Am Soci Nephrol. 17:3325–3335. 2006. View Article : Google Scholar

45 

Zhao Y, Wang Y and Zhu WG: Applications of post-translational modifications of FoxO family proteins in biological functions. J Mol Cell Biol. 3:276–282. 2011. View Article : Google Scholar : PubMed/NCBI

46 

Wilk A, Urbanska K, Yang S, Wang JY, Amini S, Del Valle L, Peruzzi F, Meggs L and Reiss K: Insulin-like growth factor-I-forkhead box O transcription factor 3a counteracts high glucose/tumor necrosis factor-α-mediated neuronal damage: Implications for human immunodeficiency virus encephalitis. J Neurosci Res. 89:183–198. 2011. View Article : Google Scholar : PubMed/NCBI

Related Articles

  • Abstract
  • View
  • Download
  • Twitter
Copy and paste a formatted citation
Spandidos Publications style
Li J and Zheng J: Theaflavins prevent cartilage degeneration via AKT/FOXO3 signaling in vitro. Mol Med Rep 19: 821-830, 2019.
APA
Li, J., & Zheng, J. (2019). Theaflavins prevent cartilage degeneration via AKT/FOXO3 signaling in vitro. Molecular Medicine Reports, 19, 821-830. https://doi.org/10.3892/mmr.2018.9745
MLA
Li, J., Zheng, J."Theaflavins prevent cartilage degeneration via AKT/FOXO3 signaling in vitro". Molecular Medicine Reports 19.2 (2019): 821-830.
Chicago
Li, J., Zheng, J."Theaflavins prevent cartilage degeneration via AKT/FOXO3 signaling in vitro". Molecular Medicine Reports 19, no. 2 (2019): 821-830. https://doi.org/10.3892/mmr.2018.9745
Copy and paste a formatted citation
x
Spandidos Publications style
Li J and Zheng J: Theaflavins prevent cartilage degeneration via AKT/FOXO3 signaling in vitro. Mol Med Rep 19: 821-830, 2019.
APA
Li, J., & Zheng, J. (2019). Theaflavins prevent cartilage degeneration via AKT/FOXO3 signaling in vitro. Molecular Medicine Reports, 19, 821-830. https://doi.org/10.3892/mmr.2018.9745
MLA
Li, J., Zheng, J."Theaflavins prevent cartilage degeneration via AKT/FOXO3 signaling in vitro". Molecular Medicine Reports 19.2 (2019): 821-830.
Chicago
Li, J., Zheng, J."Theaflavins prevent cartilage degeneration via AKT/FOXO3 signaling in vitro". Molecular Medicine Reports 19, no. 2 (2019): 821-830. https://doi.org/10.3892/mmr.2018.9745
Follow us
  • Twitter
  • LinkedIn
  • Facebook
About
  • Spandidos Publications
  • Careers
  • Cookie Policy
  • Privacy Policy
How can we help?
  • Help
  • Live Chat
  • Contact
  • Email to our Support Team